Sionna Therapeutics (SION) said late Thursday it has priced an initial public offering of about 10.6 million shares at $18 per share for expected gross proceeds of $191 million.
The cystic fibrosis-focused pharmaceutical firm said its shares are scheduled to begin Nasdaq trading Friday under the ticker symbol "SION."
Sionna has also granted underwriters a 30-day option to purchase up to about 1.6 million additional shares.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。